477P - Distinctive impact of whole-body metastases on the survival outcomes according to the histological subtypes in advanced non-small cell lung cancer
|Date||18 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Non-Small-Cell Lung Cancer, Metastatic
|Presenter||Dong Soo Lee|
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix139-ix156. 10.1093/annonc/mdw594|
D.S. Lee1, S.J. Kim2, Y.H. Ko3, J.W. Kim4, H.S. Jang5, Y.S. Kim5, J.H. Kang6
We launched this study to investigate the influence of whole-body metastases (WBM) on the survival outcomes according to the histological subtypes in stage IV non-small cell lung cancer (NSCLC).
Between June 2007 and June 2013, a total of 474 patients were included and analyzed. These patients were histologically proven as NSCLC and underwent systemic imaging work-up procedures. Synchronous WBM sites were categorized into 7 areas with the following: abdomen/pelvis; lung to lung or pulmonary lymphangitic spread; bone (skeletal system); pleural and/or pericardial metastasis; upper neck and/or axillary lymph nodes (LNs); other soft tissue; and brain. WBM scores were calculated from 1 to 7 by summation of each involved region. The patient, tumor, metastatic characteristics and the impact of WBM on overall survival (OS) were compared according to the histological subtypes.
The enrolled study population comprised 82.9% (n = 393) non-squamous cell carcinoma (non-SQ) patients and 17.1% (n = 81) squamous cell carcinoma (SQ) patients. In the univariate survival analysis of SQ subgroup, gender (p = 0.009), age (p
Although this study is limited due to small sample sizes, WBM significantly affected survival outcomes especially in the non-SQ populations. The indwelling relationship between WBM and OS should be further explored in the future studies.
Clinical trial indentification
Legal entity responsible for the study
All authors have declared no conflicts of interest.